期刊文献+

唑来膦酸联合钙剂治疗原发性骨质疏松的临床疗效 被引量:3

Clinical efficacy of zoledronic acid combined with calcium in the treatment of primary osteoporosis
原文传递
导出
摘要 目的探究唑来膦酸联合钙剂治疗原发性骨质疏松(OP)的临床疗效。方法选择180例OP患者,并平均随机分为研究组和对照组。对两组患者均给与口服碳酸钙D3片(Ⅱ),在此基础上研究组患者合并接受唑来膦酸注射治疗,治疗12个月后观察临床疗效并统计总有效率。采集所有患者在治疗前和治疗后的骨密度,疼痛视觉模拟评分(VAS),以及骨生化指标,包括血钙(Ca)、血磷(P)、骨γ-羧基谷氨酸蛋白(BGP)和降钙素(hCT)、Ⅰ型胶原氨基端肽(P1NP)和Ⅰ型胶原交联羧基末端肽(β特异性序列)(β-CTX)。结果研究组的临床疗效好于对照组(P<0.05)。治疗后,研究组患者的骨密度高于对照组(P<0.05),VAS评分低于对照组(P<0.05)。治疗后,对照组和研究组的血钙、血磷和BGP的差异不显著(均P>0.05),研究组的hCT和P1NP水平高于治疗前(均P<0.01),β-CTX水平低于治疗前(P<0.01)。结论唑来膦酸联合钙剂对OP具有较好的治疗效果。 Objective To investigate the clinical efficacy of zoledronic acid combined with calcium in the treatment of primary osteoporosis(OP).Methods A total of 180 patients with OP were selected and randomly divided into study group and control group.The two groups of patients were given oral calcium carbonate D3 tablets(Ⅱ),on this basis,the patients in the study group were given zoledronic acid injection.The clinical efficacy was observed after 12 months of the treatment,and the total effective rate was calculated.The bone mineral density,visual analog scale(VAS)of pain,and bone biochemical indexes,including blood calcium(Ca),blood phosphorus(P),boneγ-carboxyglutamate protein(BGP),calcitonin(hCT),collagen type I amino-terminal peptide(P1NP)and collagen type I cross-linked carboxy-terminal peptide(β-specific sequence)(β-CTX)were collected before and after the treatment.Results The clinical efficacy of the study group was better than that of the control group(P<0.05).After the treatment,the bone mineral density in the study group was higher(P<0.05),and the VAS score was lower than that in the control group(P<0.05).After the treatment,there was no significant difference in serum calcium,serum phosphorus and BGP between the control group and the study group(all P>0.05),the hCT and P1NP levels in the study group were significantly higher than those before the treatment(all P<0.01),and theβ-CTX level was significantly lower than that before the treatment(P<0.01).Conclusions Zoledronic acid combined with calcium has a good therapeutic effect on OP.
作者 陈京伟 王巨鹏 李猛 赵成礼 Chen Jingwei;Wang Jupeng;Li Meng;Zhao Chengli(The Second Department of Orthopedics,Tianjin Xiqing Hospital,Tianjin 300380,China)
出处 《国际生物医学工程杂志》 CAS 2022年第1期64-67,72,共5页 International Journal of Biomedical Engineering
关键词 骨质疏松 唑来膦酸 钙剂 骨密度 骨疼痛 Osteoporosis Zoledronic acid Calcium Bone mineral density Bone pain
  • 相关文献

参考文献7

二级参考文献68

  • 1张昆,路燕燕,刘熹,余晨.血磷正常的慢性肾脏病患者矿物质骨代谢异常的相关性因素分析[J].世界临床医学,2018,12(1):1-1. 被引量:2
  • 2E. K. Spanakis,D. E. Sellmeyer.Nonuremic calciphylaxis precipitated by teriparatide [rhPTH(1–34)] therapy in the setting of chronic warfarin and glucocorticoid treatment[J]. Osteoporosis International . 2014 (4)
  • 3Mara J Horwitz,Marilyn Augustine,Leila Kahn,Emily Martin,Christine C Oakley,Raquel M Carneiro,Mary Beth Tedesco,Angela Laslavic,Susan M Sereika,Alessandro Bisello,Adolfo Garcia‐Oca?a,Caren M Gundberg,Jane A Cauley,Andrew F Stewart.A comparison of parathyroid hormone‐related protein (1‐36) and parathyroid hormone (1‐34) on markers of bone turnover and bone density in postmenopausal women: The PrOP study[J]. J Bone Miner Res . 2013 (11)
  • 4Henrik Daugaard,Brian Elmengaard,Troels Torp Andreassen,Anders Lamberg,Joan Elisabeth Bechtold,Kjeld Soballe.Systemic intermittent parathyroid hormone treatment improves osseointegration of press-fit inserted implants in cancellous bone[J]. Acta Orthopaedica . 2012 (4)
  • 5Yanfei LMa,QingqiangZeng,David WDonley,Louis‐GeorgesSte‐Marie,J ChristopherGallagher,Gail PDalsky,RobertMarcus,Erik FinkEriksen.Teriparatide Increases Bone Formation in Modeling and Remodeling Osteons and Enhances IGF‐II Immunoreactivity in Postmenopausal Women With Osteoporosis[J]. J Bone Miner Res . 2009 (6)
  • 6Silvano Adami,Alessandra Zivelonghi,Vania Braga,Elena Fracassi,Davide Gatti,Maurizio Rossini,Fabio M. Ulivieri,Ombretta Viapiana.Insulin-like growth factor-1 is associated with bone formation markers, PTH and bone mineral density in healthy premenopausal women[J]. Bone . 2009 (1)
  • 7Audrey Neuprez.Bone-forming agents in the management of osteoporosis[J]. Best Practice & Research Clinical Endocrinology & Metabolism . 2008 (5)
  • 8J.H. Jeon,D.A. Puleo.Formulations for Intermittent Release of Parathyroid Hormone (1-34) and Local Enhancement of Osteoblast Activities[J]. Pharmaceutical Development and Technology . 2008 (6)
  • 9John P. Bilezikian.Combination anabolic and antiresorptive therapy for osteoporosis: Opening the anabolic window[J]. Current Osteoporosis Reports . 2008 (1)
  • 10Khosla Sundeep.The bone and beyond: a shift in calcium. Nature Medicine . 2011

共引文献1849

同被引文献26

引证文献3

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部